CN1471919A - Use of allose alcohol in preparing medicine for diabetes - Google Patents

Use of allose alcohol in preparing medicine for diabetes Download PDF

Info

Publication number
CN1471919A
CN1471919A CNA021335621A CN02133562A CN1471919A CN 1471919 A CN1471919 A CN 1471919A CN A021335621 A CNA021335621 A CN A021335621A CN 02133562 A CN02133562 A CN 02133562A CN 1471919 A CN1471919 A CN 1471919A
Authority
CN
China
Prior art keywords
allit
mice
allitol
medicine
behind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA021335621A
Other languages
Chinese (zh)
Other versions
CN1291721C (en
Inventor
马耀辉
邓岚
苏任
曹家麒
马丽英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUNNAN INSTITUTE OF MICROBIOLOGY
Original Assignee
YUNNAN INSTITUTE OF MICROBIOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YUNNAN INSTITUTE OF MICROBIOLOGY filed Critical YUNNAN INSTITUTE OF MICROBIOLOGY
Priority to CN 02133562 priority Critical patent/CN1291721C/en
Publication of CN1471919A publication Critical patent/CN1471919A/en
Application granted granted Critical
Publication of CN1291721C publication Critical patent/CN1291721C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An application of allitol in preparing the medicines for treating diabetes is disclosed. Its advantages are high safety, slow and smooth hypoglycemic procedure, and high effect to improve the life quality of diabetic and prevent and treat the complication of diabetes.

Description

The application of Allit in the preparation diabetes medicament
Technical field: the present invention relates to of the application of a kind of Allit as the preparation Rezulin.
Background technology: at present, diabetes are called as lifelong disease, go back neither one country and can effect a radical cure.The main harm that generally believes diabetes now derives from hyperglycemia, and Drug therapy obtains prolonging by Blood glucose control being made life mainly based on blood sugar control.Cordyceps is the traditional food of China, the dual-purpose treasure of medicine, and motherland's traditional medicine and modern medicine study show that Cordyceps has therapeutical effect preferably to multiple chronic disease.In recent years, utilize biofermentation technique cultivation Cordyceps quite a lot as the product of health food and treatment medicine.We had 10 years the research of Cordyceps, successively finished " research of Cordyceps Application and Development " and " Cordyceps polysaccharide applied research ", and it were a plurality of to have developed the Cordyceps series of products.For many years in difference use crowd, often there is this product multiple chronic disease to be had the information feedback of obvious therapeutic effect, particularly from the reflection of diabetics, think better curative effect is arranged, for further furtheing investigate the effective ingredient in the Cordyceps, we carry out work such as separation and purification with Cordyceps fermented product, obtain a kind of unification compound Allit (allitol) in isolated material.Allit (allitol) is that occurring in nature exists a few compounds, about the biological activity and the application at aspects such as medical treatment of Allit (allitol) there is no report.
Summary of the invention: the object of the present invention is to provide the purposes of a kind of Allit, be used for smelting and treat diabetes as preparation smelting treatment Rezulin.
The present invention is such realization: Allit is treated the purposes of Rezulin as the preparation smelting.
Description of drawings: table 1 is before the administration of Allit (allitol) 3mg/kg group and blood glucose value contrast after the administration.
Table 2 is dead mouse situation contrast during the administration under Allit (allitol) the content 3mg/kg state.
Table 3 is before the administration of Allit (allitol) 4mg/kg group and blood glucose value contrast after the administration.
Table 4 is dead mouse situation contrast during the administration under Allit (allitol) the content 4mg/kg state.
Table 5: Allit (allitol) is (3mg/kg) to the observed and recorded of mice growth and life quality influence.
Table 6: Allit (allitol) is (3mg/kg) to the influence of mouse blood sugar.
Table 7: Allit (allitol) is (4mg/kg) to the observed and recorded of mice growth and life quality influence.
Table 8: Allit (allitol) is (4mg/kg) to the influence of mouse blood sugar.
Table 9: to administration phase two groups of Allits (allitol) (content is 3mg/kg and 4mg/kg) average blood sugar value variation diagram.
Table 10: Allit (allitol) is to animal white mice toxicological experiment.
Specific embodiments: following just Allit of the present invention (allitol) is treated the purposes of Rezulin as the preparation smelting, provide the experiment of Allit (allitol) animal toxicology, Allit (allitol) changes of contents to animal blood glucose and growth and life quality influence and Allit (allitol) to the blood sugar lowering of diabetic mice and the effect of curative effect.By the diabetic mice experiment of model induced by alloxan, experiment Allit (allitol) is to the blood sugar lowering of diabetic mice and the effect of curative effect.
1.1 supply the reagent product: Allit (allitol) is by extracting in the Cordyceps fermented product, and purity is more than 90%, with aquae destillata preparation (0.1mg/ml)
1.2 experimental animal: the ICR mice, male, economize natural drug key lab by unming Medical College (the 9804th, No. 9806 environment of the real moving card font size in Yunnan, the certification of fitness) is provided
1.3 diabetic mice Preparation of model: normal health mice fasting 8 hours, freely drink water, by the disposable quick injection of tail vein (in the 30s) alloxan 60mg/kg.After intravenous injection, get blood from mouse tail vein on the 4th day and survey blood glucose.The mice of blood glucose value>12mmol/L is decided to be diabetic mice.
1.4 grouping of mice and medication: diabetic mice is divided into matched group and administration group at random by blood glucose value, and other establishes one group of normal group, controlled observation mice growth conditions and quality of life.Matched group and administration group adopt gastric infusion, once a day.The administration group is given ST by 3mg/kg group, 4mg/kg body weight dosage, and matched group is given the aquae destillata of equivalent.After administration a period of time, survey the mice postprandial plasma glucose level, from tail vein get blood after being determined at administration 1hr at every turn.
2. the results are shown in Table 1: matched group cause death rate height, only surplus 2, wherein 1 recovery naturally, can't comparable group between significant difference.
There is the utmost point significant difference P<0.01 before Allit (allitol) the group giving drugs into nose, behind the medicine.
" * " is that mice is dead.
Table 1: Allit (allitol) 3mg/kg organizes before the administration and blood glucose value contrast after the administration:
Matched group blood glucose value (14 example) Allit (allitol) group blood glucose value (11 example)
Numbering Before the medicine Behind the medicine 4 months Behind the medicine 6 months Before the medicine Behind the medicine 4 months Behind the medicine 6 months
????1 ????25.8 ???* ???* ????25.4 ???9.2 ????5.8
????2 ????23.2 ???27.1 ???23.3 ????25.3 ???15.1 ????7.1
????3 ????20.8 ???26.9 ???* ????15.9 ???7.6 ????6.8
????4 ????16.9 ???* ???* ????13.9 ???8.7 ????7.1
????5 ????16 ???23.4 ???* ????22.7 ???22.7 ????28
????6 ????27.6 ???19 ???* ????27.3 ???15.2 ????8.8
????7 ????13.2 ???* ???* ????18.8 ???23.2 ????26.5
????8 ????12.1 ???* ???* ????15.9 ???7.1 ????5.3
????9 ????21.8 ???* ???* ????26.5 ???18 ????13.7
????10 ????27.3 ???* ???* ????24.5 ???14.9 ????7.8
????11 ????26.6 ???* ???* ????17.7 ???* ????*
????12 ????24.7 ???5.8 ???6.4
????13 ????27.6 ???* ???*
????14 ????12.8 ???* ???*
Meansigma methods ????21.17 ???20.44 ???14.85 ????21.26 ???14.17 ????11.69
Table 3: before Allit (allitol) the 4mg/kg administration and blood glucose value contrast after the administration:
Matched group blood glucose value (13 example) Allit (allitol) group blood glucose value (12 example)
Numbering Before the medicine Behind the medicine 4 months Behind the medicine 6 months Before the medicine Behind the medicine 4 months Behind the medicine 6 months
????1 ??23.6 ???* ???* ????26.4 ?7.9 ????5.9
????2 ??25.2 ???27.6 ???24.3 ????26.2 ?8.8 ????8.0
????3 ??21.8 ???* ???* ????21.7 ?7.6 ????6.7
????4 ??18.3 ???18.5 ???23.2 ????12.8 ?7.4 ????6.1
????5 ??15.2 ???21.2 ???* ????15.7 ?9.2 ????6.2
????6 ??21.4 ???* ???* ????19.3 ?* ????*
????7 ??15.1 ???23.4 ???* ????18.6 ?8.7 ????7.9
????8 ??27.6 ???* ???* ????26.8 ?6.2 ????7.8
????9 ??23.4 ???5.6 ???* ????14.9 ?6.4 ????7.4
????10 ??27.3 ???* ???* ????26.5 ?26 ????15.9
????11 ??21.7 ???27.9 ???26.8 ????23.7 ?* ????*
????12 ??17.1 ???* ???* ????27.3 ?27.2 ????28
????13 ??21.39 ???* ???*
Meansigma methods ??21.47 ???20.70 ???24.76 ????21.65 ?11.54 ????9.99
Matched group cause death rate height, only surplus 3, can't comparable group between significant difference.
There is the utmost point significant difference P<0.01 before Allit (allitol) the group giving drugs into nose, behind the medicine.
" * " is that mice is dead.
Table 2: dead mouse situation contrast during the administration:
Matched group death condition (14 example) Allit (allitol) group death condition (11 example)
1 month 3 months 6 months 1 month 3 months 6 months
Accumulation death toll (only) ??4 ??7 ??12 ????1
Mortality rate ???????????????85% ????????????????9%
Dead mouse situation contrast during table 4 administration:
Matched group death condition (13 example) Allit (allitol) group death condition (12 example)
1 month 3 months 6 months 1 month 3 months 6 months
Accumulation death toll (only) ??3 ??6 ??10 ??1
Mortality rate ???????????????77% ???????????????????8.4%
Allit (allitol) is different from general hypoglycemic drug, and the blood sugar lowering process is slowly steady, hypoglycemia danger can not take place even take in a large number also, takes safety.Diabetic mice is through taking Allit (allitol) continuously after six months, and postprandial plasma glucose level is tending towards normally gradually, and diabetic symptom is eliminated gradually; 3mg/kg organizes invalid 3 examples (containing dead mice), and effective percentage is 72%.Mouse blood sugar value of matched group is recovered normally to account for 7% naturally; 4mg/kg organizes invalid 3 examples (containing dead mice), and effective percentage is 75%.The control group mice blood glucose value does not have obvious recovery.
Control group mice after suffering from diabetes, the acute and chronic complicating diseases (two groups of average mortalities are more than 80%) that the forward and backward phase all has more mice to die from diabetes to cause.Take Allit (allitol) though mice still is in hyperglycemia state early stage, under the situation of not taking other antidiabetic drug, Allit (allitol) has been controlled the generation of mice diabetic complication under the hyperglycemia state effectively.Mortality rate is than the remarkable reduction of matched group (average mortality is below 10%).
According to the paired observation of normal group mice, it is poor slightly that the diabetic mice of taking Allit (allitol) removes early stage spirit, later stage and normal group are as good as substantially.Energetic, active, trophophase mice body weight normally increases well-grown.Do not take the diabetic mice of Allit (allitol), lethargy, the mice weight increase of trophophase is slow, and growth is subjected to remarkable inhibition.The long-term nursing, the mice of taking Allit (allitol) does not have intoxicating phenomenon and untoward reaction.
Table 5: Allit (allitol) is (3mg/kg) to observed and recorded date of mice growth and life quality influence: 30 on April 20th, 1 2002 of calendar year 2001 JIUYUE
Group Normal group Matched group Allit (allitol)
Example number (only) 12 14 11
Average weight before the administration 21.78 22.34 22.13
Behind the medicine 1 month Average weight Survival condition Average weight Survival condition Average weight Survival condition
30.2g Good 28.4 Compare with normal group, spirit is poor.Drink water and urinate obviously many.80% mice becomes thin.Spirit is poor.This month four death, 30.1 Compare with normal group, 30% mice does not have significant difference, and 70% spirit is relatively poor.Drink water and urinate obviously many.
2 months 36.1 Good 30.8 Compare with normal group, spirit is poor.Drink water and urinate obviously many.Part mice anus is red and swollen or fester.This month death, 34.5 Mice spirit is clearly better, and 80% mice and normal group do not have significant difference, and 20% spirit is relatively poor.Drink water and urinate obviously many.
3 months 39.7 Good 34.6 Compare with normal group, spirit is poor.Drink water and urinate obviously many.Part mice anus or back leg are red and swollen and fester.This month two death, 37.42 Except that drink water and urinate how than normal group.Mice spirit and normal group do not have obvious difference.Blood glucose value significantly reduces.This month death.
4 months 41.5 The death of good this month 34.1 In last five mices, drink water and urinate obviously many.Most spirit are poor.This month two death, 39.4 In high spirits, drink water and urinate and more preceding month obviously reduce.
5 months 41.8 Good 35.6 Last three mices, two spirit are better, and one is poor.This month two death, 40 In high spirits, drink water and urinate and more preceding month obviously reduce.Substantially normal.
6 months Good Dead one.
Mortality rate 10% 85% 9%
Table 6: Allit (allitol) is (3mg/kg) to date that influences of mouse blood sugar: 30 on April 20th, 1 2002 of calendar year 2001 JIUYUE
Matched group Allit (allitol)
Numbering Blood glucose before the medicine 1 week behind the medicine 2 weeks behind the medicine January behind the medicine March behind the medicine April behind the medicine June behind the medicine Numbering Blood glucose before the medicine 1 week behind the medicine 2 weeks behind the medicine January behind the medicine March behind the medicine April behind the medicine June behind the medicine
??1 ??25.8 ??22.8 ??24.1 ??21.4 ??9.1 ????* ????* ????1 ??25.4 ????19.1 ????16.3 ????23.1 ????16.2 ????9.2 ????5.8
??2 ??23.2 ??27.6 ??23.3 ??25.6 ??27.1 ????27.1 ????23.3 ????2 ??25.3 ????26.3 ????23.1 ????23.8 ????15.3 ????15.1 ????7.1
??3 ??20.8 ??28.1 ??27.6 ??27 ??26.9 ????26.9 ????* ????3 ??15.9 ????24.4 ????27.4 ????23.4 ????12.1 ????7.6 ????6.8
??4 ??16.9 ??6.6 ??9.7 ??7.4 ??* ????* ????* ????4 ??13.9 ????10.5 ????23.4 ????6.7 ????9.7 ????8.7 ????7.1
??5 ??16 ??10.3 ??21.9 ??25.9 ??23.4 ????23.4 ????* ????5 ??22.7 ????18.9 ????6.7 ????27.1 ????24.8 ????22.7 ????28
??6 ??27.6 ??25.1 ??22.2 ??19.5 ??19 ????19 ????* ????6 ??27.3 ????5.1 ????17.1 ????18.4 ????17.2 ????15.2 ????8.8
??7 ??13.2 ??9.2 ??11.7 ??* ??* ????* ????* ????7 ??18.8 ????17.6 ????18.4 ????24.2 ????27.3 ????23.2 ????26.5
??8 ??12.1 ??6.8 ??6.8 ??* ??* ????* ????* ????8 ??15.9 ????25.1 ????24.2 ????27.3 ????9.8 ????7.1 ????5.3
??9 ??21.8 ??12.4 ??12.9 ??26.8 ??* ????* ????* ????9 ??26.5 ????12.1 ????12.1 ????12.1 ????10.4 ????18 ????13.7
??10 ??27.3 ??27.5 ??27.6 ??27.4 ??12.7 ????* ????* ????10 ??24.5 ????27.1 ????25.1 ????25.1 ????16.2 ????14.9 ????7.8
??11 ??26.6 ??28 ??6.4 ??* ??* ????* ????* ????11 ??17.7 ????4.6 ????22.5 ????22.5 ????25.9 ????* ????*
??12 ??24.7 ??25.2 ??24.9 ??9.7 ??5.8 ????5.8 ????6.4
??13 ??27.6 ??27.9 ??28 ??28.3 ??* ????* ????*
??14 ??12.8 ??14.8 ??7.4 ??* ??* ????* ????*
Meansigma methods ??21.17 ?19.45 ??18.17 ??21.9 ??17.71 ???20.44 ????14.85 ??21.26 ????17.34 ????21.89 ????23.86 ????16.64 ????15.17 ????11.69
" * " is that mice is dead in the table.
Table 7: Allit (allitol) is (4mg/kg) to observed and recorded date of mice growth and life quality influence: April 20-2002 October 30 of calendar year 2001
Group Normal group Matched group Allit (allitol)
Example number (only) 12 13 12
Average weight before the administration 21.78 21.25 21.37
Behind the medicine 1 month Average weight Survival condition Average weight Survival condition Average weight Survival condition
30.2g Good 27.9 Compare with normal group, spirit is poor.Drink water and urinate obviously many.80% mice becomes thin.This month two death, 28.9 Compare with normal group, 20% mice does not have significant difference, and 80% spirit is relatively poor.Drink water and urinate obviously many.This month 2 death.
2 months 36.1 Good 30.4 Compare with normal group, spirit is poor.Drink water and urinate obviously many.Part mice anus is red and swollen or fester.An eye is blind.This month death, 32.4 Mice spirit is clearly better, and 60% mice and normal group do not have significant difference, and 40% spirit is relatively poor.Drink water and urinate obviously many.
3 months 39.7 Good 32.5 Compare with normal group, spirit is poor.Drink water and urinate obviously many.This month three death, 35.2 Except that drink water and urinate how than normal group.Mice spirit and normal group do not have obvious difference.Blood glucose value significantly reduces.
4 months 41.5 The death of good this month 33.2 In last five mices, drink water and urinate obviously many.Three mice spirit are better, and two obvious poor.This month two death, 38.5 In high spirits, drink water and urinate and more preceding month obviously reduce.
5 months 41.8 Good 34.8 Last three mices, two spirit are better, and one is poor.Majority festers for anus before this month death, matched group death. 39.1 In high spirits, drink water with to urinate the fundamental sum normal group consistent.
6 months Good Dead one. The same
Mortality rate 10% 77% 8.4%
Table 8: Allit (allitol) is (4mg/kg) to date that influences of mouse blood sugar: April 20-2002 October 8 of calendar year 2001
Matched group Allit (allitol)
Numbering Blood glucose before the medicine 1 week behind the medicine 2 weeks behind the medicine January behind the medicine March behind the medicine April behind the medicine June behind the medicine Numbering Blood glucose before the medicine 1 week behind the medicine 2 weeks behind the medicine January behind the medicine March behind the medicine April behind the medicine June behind the medicine
??1 ??23.6 ??21.7 ????25.2 ??26.1 ????* ????27.6 ????27.6 ????1 ??26.4 ??11.7 ????8.6 ????19.6 ????7.7 ????7.9 ????5.9
??2 ??25.2 ??27.5 ????26.5 ??22.4 ????20.1 ????* ????* ????2 ??26.2 ??5.8 ????22.7 ????28 ????15.7 ????8.8 ????8
??3 ??21.8 ??28.2 ????24.3 ??25.1 ????* ????18.5 ????23.2 ????3 ??21.7 ??20.7 ????24.3 ????10.9 ????10.3 ????7.6 ????6.7
??4 ??18.3 ??12.9 ????14.8 ??13.2 ????17.6 ????21.2 ????* ????4 ??12.8 ??19.1 ????22 ????25.7 ????13.9 ????7.4 ????6.1
??5 ??15.2 ??25.2 ????15.1 ??23.5 ????18.9 ????23.4 ????* ????5 ??15.7 ??4.5 ????19.1 ????20.5 ????9.1 ????9.2 ????6.2
??6 ??21.4 ??23.1 ????24.5 ??21.3 ????21.5 ????* ????* ????6 ??19.3 ??26.9 ????5.9 ????* ????* ????* ????*
??7 ??15.1 ??8.9 ????6.3 ??* ????* ????* ????* ????7 ??18.6 ??19.8 ????18.3 ????20.2 ????11 ????8.7 ????7.9
??8 ??27.6 ??19.8 ????22.6 ??25.6 ????24.3 ????5.6 ????* ????8 ??26.8 ??28 ????16.1 ????20.3 ????8.8 ????6.2 ????7.8
??9 ??23.4 ??27.5 ????26.4 ??* ????* ????* ????* ????9 ??14.9 ??13.9 ????8.7 ????16.9 ????10.9 ????6.4 ????7.4
??10 ??27.3 ??22.5 ????22.3 ??19.9 ????* ????* ????* ????10 ??26.5 ??24 ????23 ????27.8 ????21.5 ????26 ????15.9
??11 ??21.7 ??25.3 ????27.6 ??26.9 ????24.1 ????27.9 ????26.8 ????11 ??23.7 ??27.8 ????12.5 ????* ????* ????* ????*
??12 ??17.1 ??12.1 ????8.9 ??7.4 ????* ????* ????* ????12 ??27.3 ??28 ????27.9 ????26.9 ????27.4 ????27.2 ????28
??13 ??21.39 ??* ????* ??* ????* ????* ????*
Meansigma methods ??21.47 ???21.22 ????20.37 ??21.14 ????21.08 ????20.7 ????24.76 ??21.65 ??19.18 ????17.42 ????21.68 ????13.63 ????11.54 ????9.99
" * " is that mice is dead in the table.
From the experimental study result, Allit (allitol) is a slow progressive process to the therapeutical effect of diabetic mice.In the medication treatment process, the quality of life that Allit (allitol) has obviously improved diabetic mice, reduced the generation of complication, the mortality rate of diabetic mice is significantly reduced.The blood glucose value of diabetic mice is tending towards gradually with the prolongation of medication treatment time normally, and does not see the bounce-back of mouse blood sugar value after the drug withdrawal.From above situation, the mechanism of action of Allit (allitol) may be different from existing Remedies for diabetes.
Table 9 is respectively organized Allit (allitol) (3mg/kg, 4mg/kg) average blood sugar value variation diagram for the administration phase.
The administration phase is respectively organized average blood sugar value variation diagram
The toxicological test purpose: its mouse oral acute toxicity testing (LD50), understand the toxicity intensity, character and the possibility target organ that are tried thing Allit (allitol).The date of inspection: on April 5th, 2002
Inspection product title: (extracted by Cordyceps fermented product, purity is more than 90% for Allit (allitol).) sample concentration: needle-shaped crystals solvent: distilled water.Sample treatment: (allitol) is formulated as saturated solution with distilled water with Allit.
Select for use unming Medical College to economize 20 of the cleaning level ICR of natural drug key lab mices (the 9804th, No. 9806 environment of the real moving card font size in Yunnan, the certification of fitness).Male and female half and half, body weight 18-22g.
Because of measuring LD 50So, measure with reference to the assay method of maximum tolerated dose (MTD).Mice fasting 12hr freely drinks water.By mice heap(ed) capacity 0.4ml/10g administration, irritate stomach secondary (6hr at interval) in one day, route of administration is identical with clinical practice, daily dose 2.1g/kg, be equivalent to 700 times (calculating) of clinical consumption mice dose,equivalent, observed record poisoning symptom and animal dead situation 15 days with body surface area.
Table 10: to animal white mice toxicological experiment
Dosage (g/kg.day) Administration (2 times/day) Size of animal (only) Death toll The weight of animals (g)
Before the test After the test
??2.1 2 20 0 Female 19.03±0.81 ?24.69±1.44
Male 19.86±1.02 ?26.87±1.44
As can be seen from Table 11: the mouse stomach administration, accumulated dose is 2.1g/kg, is equivalent to 700 times of the dose,equivalents of clinical application, observes first quarter moon, the mice mental status, activity, appetite are normal, do not find any untoward reaction of mice, diarrhoea and the phenomena of mortality.The postmortem heart, lung, liver color are normal, do not have acute pathological change, and it is very little that this is tried thing toxicity.
Table 11: mouse blood sugar value laboratory observation after the drug withdrawal
Allit (allitol) group (4mg/kg) blood glucose value Allit (allitol) group (3mg/kg) blood glucose value
Numbering During drug withdrawal Drug withdrawal 35 days Drug withdrawal 90 days During drug withdrawal Drug withdrawal 35 days Drug withdrawal 90 days
????1 ????5.9 ??6.7 ??5.8 ????5.8 ??6.6 ????6.2
????2 ????8.0 ??6.5 ??6.8 ????7.1 ??5.6 ????5.4
????3 ????6.7 ??5.6 ??6.3 ????6.8 ??6.4 ????8.9
????4 ????6.1 ??6.3 ??6.0 ????7.1 ??7.1 ????6.8
????5 ????6.2 ??6.3 ??6.7 ????28 ??*
????6 ????7.9 ??7.3 ??6.4 ????8.8 ??8.6 ????5.6
????7 ????7.8 ??6.6 ??5.6 ????26.5 ??*
????8 ????7.4 ??7.7 ??6.5 ????5.3 ??5.7 ????6.8
????9 ????15.9 ??8.3 ??6.3 ????13.7 ??7.1 ??--6.2
????10 ????28 ??11.8 ??7.6 ????7.8 ??9.5 ????5.6
" * " is dead mouse between withdrawal time
The present invention treats the diabetes effect to Allit (allitol) and has carried out zoopery, and experimental result Allit (allitol) has following characteristics:
1, Allit (allitol) is different from general hypoglycemic drug, and the blood sugar lowering process is slowly steady, hypoglycemia danger can not take place even take in a large number also, takes safety.Diabetic mice is after taking six months continuously, and postprandial plasma glucose level is tending towards normally gradually, and diabetic symptom is eliminated gradually, and effective percentage is more than 70%.And do not see the bounce-back of mouse blood sugar value after the drug withdrawal.
2, take that the diabetic mice of Allit (allitol) is energetic, active, body weight normally increases, well-grown is compared with matched group, and quality of life significantly improves.The diabetic mice of not taking medicine, lethargy, the mice weight increase of trophophase is slow, and growth is subjected to remarkable inhibition, and quality of life obviously reduces.
3, control mice is after suffering from diabetes, acute and the chronic complicating diseases (mortality rate is more than 80%) that the forward and backward phase all has more mice to die from diabetes to cause, reduce (mortality rate is below 10%) greatly and take Allit (allitol) mouse death rate, show that Allit (allitol) can prevent and treat the complication that caused by diabetes and take place.
4, the long-term nursing, mice does not have intoxicating phenomenon and untoward reaction.
5, Allit (allitol) is different from the at present common blood sugar control and the medicine of blood sugar lowering, it has obvious effect to the mice growth and the raising of quality of life of suffering from diabetes and be in for a long time in the hyperglycemia state, and the complication that diabetes are caused has obvious preventive and therapeutic effect.

Claims (1)

1, Allit is treated the purposes of Rezulin as the preparation smelting.
CN 02133562 2002-07-30 2002-07-30 Use of allose alcohol in preparing medicine for diabetes Expired - Fee Related CN1291721C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02133562 CN1291721C (en) 2002-07-30 2002-07-30 Use of allose alcohol in preparing medicine for diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02133562 CN1291721C (en) 2002-07-30 2002-07-30 Use of allose alcohol in preparing medicine for diabetes

Publications (2)

Publication Number Publication Date
CN1471919A true CN1471919A (en) 2004-02-04
CN1291721C CN1291721C (en) 2006-12-27

Family

ID=34145598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02133562 Expired - Fee Related CN1291721C (en) 2002-07-30 2002-07-30 Use of allose alcohol in preparing medicine for diabetes

Country Status (1)

Country Link
CN (1) CN1291721C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103468606A (en) * 2013-08-14 2013-12-25 中国科学院天津工业生物技术研究所 Klebsiella oxytoca and application thereof in allitol production
CN113631175A (en) * 2019-03-26 2021-11-09 国立大学法人香川大学 Anti-obesity agent containing allose alcohol as effective component and obesity inhibiting method

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103468606A (en) * 2013-08-14 2013-12-25 中国科学院天津工业生物技术研究所 Klebsiella oxytoca and application thereof in allitol production
CN103468606B (en) * 2013-08-14 2015-01-07 中国科学院天津工业生物技术研究所 Klebsiella oxytoca and application thereof in allitol production
CN113631175A (en) * 2019-03-26 2021-11-09 国立大学法人香川大学 Anti-obesity agent containing allose alcohol as effective component and obesity inhibiting method

Also Published As

Publication number Publication date
CN1291721C (en) 2006-12-27

Similar Documents

Publication Publication Date Title
EP1429602B1 (en) Methods for treating disorders using plant extracts
CN106535907A (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
CN1942097A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
CN101167802B (en) Method for preparing cinnamon extraction, cinnamon extraction and its composition and use
JP5303209B2 (en) Evaluation method, screening method, and production method of substance that lowers blood glucose level
AU2021326515A1 (en) The use of variovorax microbes as an alternative treatment for coccidiosis
CN1817896A (en) Compounds like quercetol and metal complex of their glycosides and uses
CN1291721C (en) Use of allose alcohol in preparing medicine for diabetes
DE69031694T3 (en) Glutamine for the treatment of impaired immunity
GROZAVESCU et al. Biochemical aspects of diabetes mellitus
CN102114076B (en) Preparation method of cassia bark extract, cassia bark extract and composition and application thereof
CN104415023A (en) Composition for preventing or/and treating insulin resistance and related diseases
CN101574342B (en) Application of nitazoxanide in preparing drug for resisting eimeria coccidium
CN116531410A (en) Application of staphylococcus albus in preparation of composition
CN103340880B (en) Application of 2,3-dihydroxy benzoic acid ester compound in preparation of foods and medicines for treating diabetes
CN101322738A (en) Preparation of red sandalwood extract for treating diabetic and uses thereof
WO2022245171A1 (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
CN107496438B (en) Application of Phellinus linteus polysaccharide in preparing medicine and health food
CN1086289C (en) Medicine for treating diabetes and nephrosis containing rheinic acid
CN111635417B (en) Preparation method and application of tremellodon gelatinosum polyphenol for regulating intestinal flora of obese people
CN109223735B (en) Use of active compounds isolated from secondary metabolites of aspergillus versicolor
CN1839870A (en) Use of geniposide as glicetin 1 acceptor excitomotor
CN111019010A (en) Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes
WO2004048358A1 (en) Control of cancer with annonaceous extracts
CN112569282B (en) Bacteriostatic composition containing morinda citrifolia extract and abelmoschus manihot extract

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061227

Termination date: 20110730